Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

Blujepa is approved to treat females 12 and older with uncomplicated urinary tract infections, or UTIs. About half of all women will experience a UTI at some point in their lives, and about 30% will ...

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

GSK's pill, the first oral antibiotic for urinary tract infections in almost 30 years, comes as bacteria are increasingly ...

The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug approved in decades and the first in a new class of medications. British ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

Blujepa is approved to treat females 12 and older with uncomplicated urinary tract infections, or UTIs. About half of all women will experience a UTI at some point in their lives, and about 30% ...

Blujepa, the first new oral antibiotic for UTIs in 30 years, works by targeting bacterial DNA replication through dual ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

In two studies with over 3,000 women and children who had a mild UTI, Blujepa, a pill taken twice a day for five days, worked as well as or better than nitrofurantoin, a common UTI antibiotic.